← Leaderboards
Lisa A. Cavacini
Dana-Farber Cancer Institute
$5,947,978
Attributed
$7,882,313
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $694.6K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,882,313 · 8
By mechanism
R01$5,775,362 · 3
P01$1,070,507 · 2
R21$1,036,444 · 3
Top collaborators
- Katherine A Fitzgerald4 shared
- Celia A. Schiffer4 shared
- Yang Wang2 shared
Most similar at Dana-Farber Cancer Institute
Same institution · by research overlap
- Ruth Margrit Ruprecht$54,953,328
Others in their field
Top investigators on “Neutralizing Antibody”
- Barton F Haynes · Duke University$361,488,167
- Dennis R. Burton · Scripps Research Institute$328,455,703
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$262,392,049
- Lawrence Corey · Fred Hutchinson Cancer Center$257,355,255
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$139,509,763
Research focus
Neutralizing AntibodyVirusIn VivoEpitopesViralStructureHiv InfectionsDesignImmunotherapyBaseVaccine DevelopmentMonoclonal AntibodyCellsMediatingTransmission ProcessVariantViral Load ResultImmunoglobulin AInfectionIn VitroAntibodiesHiv AntibodiesPreventionImmunoglobulin G
Grant awards (25)
Structure-guided and epitope-based design of potent and broadly neutralizing nanobodies for COVID-19 mucosal immunotherapy$677,986
R01 · FY2025 · AI · contact PI
Structure-guided and epitope-based design of potent and broadly neutralizing nanobodies for COVID-19 mucosal immunotherapy$694,551
R01 · FY2023 · AI · contact PI
Structure-guided and epitope-based design of potent and broadly neutralizing nanobodies for COVID-19 mucosal immunotherapy$694,299
R01 · FY2022 · AI
Structure-guided and epitope-based design of potent and broadly neutralizing nanobodies for COVID-19 mucosal immunotherapy$664,782
R01 · FY2021 · AI
Mechanism of Potent Neutralization of HIV by IgA CD4i Antibody$397,792
R01 · FY2016 · AI · contact PI
Mechanism of Potent Neutralization of HIV by IgA CD4i Antibody$397,792
R01 · FY2015 · AI · contact PI
Mechanism of Potent Neutralization of HIV by IgA CD4i Antibody$364,644
R01 · FY2014 · AI · contact PI
Mechanism of Potent Neutralization of HIV by IgA CD4i Antibody$408,900
R01 · FY2013 · AI · contact PI
Arming Neutrophils for the Destruction of HIV by Anti-HIV Antibody$333,234
R01 · FY2011 · AI · contact PI
Arming Neutrophils for the Destruction of HIV by Anti-HIV Antibody$380,454
R01 · FY2010 · AI · contact PI
Arming Neutrophils for the Destruction of HIV by Anti-HIV Antibody$395,126
R01 · FY2009 · AI · contact PI
Arming Neutrophils for the Destruction of HIV by Anti-HIV Antibody$365,802
R01 · FY2008 · AI · contact PI
Mucosal Protection Against HIV Transmission by Combinations of Anti-HIV Antibodie$240,344
R21 · FY2008 · AI · contact PI
Mucosal Protection Against HIV Transmission by Combinations of Anti-HIV Antibodie$212,500
R21 · FY2007 · AI · contact PI
Supplement - Humoral Immune Responses to HIV Clade C Isolates$276,804
P01 · FY2006 · AI · contact PI
Core--Antibody$72,707
P01 · FY2005 · DE
Core--Antibody$70,589
P01 · FY2004 · DE
Human Monoclonal Antibodies to Replace VIG for Therapy$170,000
R21 · FY2003 · AI
Core--Antibody$68,000
P01 · FY2003 · DE
Humoral immune responses to HIV clade C isolates$171,469
P01 · FY2002 · AI
Human Monoclonal Antibodies to Replace VIG for Therapy$170,000
R21 · FY2002 · AI
Core--Antibody$68,000
P01 · FY2002 · DE
Humoral immune responses to HIV clade C isolates$171,469
P01 · FY2001 · AI
HUMAN ANTIBODIES TO INTACT VIRIONS FOR VACCINE RESEARCH$243,600
R21 · FY2000 · AI
Humoral immune responses to HIV clade C isolates$171,469
P01 · FY2000 · AI